NCT03650608View on ClinicalTrials.gov

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Healthy Subject

Interventions

DRUG

Cohort 1: HL217 Ophathalmic Solution QD

Cohort 1 (Once a day)

DRUG

Cohort 2: HL217 Ophathalmic Solution BID

Cohort 2 (Twice a day)

DRUG

Cohort 3: HL217 Ophthalmic Solution QID

Cohort 3 (Four times a day)

DRUG

Placebo Ophthalmic solution

Placebo

All Listed Sponsors

lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT03650608 - A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects | Biotech Hunter | Biotech Hunter